119-HR-2821 Investigative Journalist Impact Analysis

Summary

What the bill does. H.R. 2821 (FDA Modernization Act 3.0) directs HHS/FDA to issue an interim final rule updating multiple CFR provisions to replace references to “animal” tests with “nonclinical” tests and to insert the statutory definition of “nonclinical test” from 21 U.S.C. §355(z); it also authorizes immediate effectiveness of the interim rule. [1]Congress.gov — Text - H.R.2821 - 119th Congress (2025-2026): FDA Modernization…

Why this matters. Congress already amended FDCA §505(i) in 2022 to remove the default “animal testing” phrasing and defined “nonclinical test”; FDA has since stood up guidance and programs to operationalize NAMs. The bill compels regulatory text to catch up, potentially reducing ambiguity for sponsors and reviewers. [2]U.S. Government Publishing Office — Public Law 117-328 (Consolidated Appropriat…

Trajectory. The House Energy & Commerce Health Subcommittee forwarded H.R. 2821 by voice vote on May 13, 2026, and the full Committee ordered it reported 44–0 on May 21, 2026—suggesting broad bipartisan support for technical alignment rather than a substantive change in evidentiary standards. [3]House Energy & Commerce Committee — Health Subcommittee Advances Policies to Im…

Economic Effects

Signals to capital and R&D portfolios hinge on whether clarity around NAMs lowers preclinical cost/time without compromising safety; evidence is promising but uneven across modalities.

• Regulatory clarity can reduce process friction. By codifying “nonclinical” across IND/NDA/BLA‑relevant CFR sections, FDA reduces interpretive mismatch with FDCA §505 and recent draft guidance on how to validate and submit NAMs—lowering uncertainty costs in pre‑IND planning and CMC/nonclinical strategy. [1]Congress.gov — Text - H.R.2821 - 119th Congress (2025-2026): FDA Modernization…
• Potential cost/time savings from NAMs where fitness‑for‑purpose is demonstrated. Expert elicitation studies on organ‑on‑chip suggest 10–26% reductions in R&D cost per new drug, driven by earlier No‑Go decisions and fewer iterative animal studies; FDA’s NAMs program and new draft guidance aim to channel validation toward such high‑impact contexts. [4]Cell Press / Elsevier — Impact of organ‑on‑a‑chip technology on pharmaceutical…
• Impact on clinical attrition is the big economic lever. Overall likelihood of approval (Phase I→approval) during 2011–2020 was about 7.9%; even small improvements in preclinical predictivity (fewer toxicology‑related failures) can yield large portfolio savings. [5]BIO / QLS / Informa Pharma Intelligence — Clinical Development Success Rates an…
• Up‑front costs and capability gaps. Sponsors—especially smaller biotechs and CROs—face investments in NAM validation, quality systems, and staff training; FDA’s framework and OECD GIVIMP emphasize method standardization, documentation, and reproducibility, which carry compliance costs before efficiencies materialize. [6]FDA — General Considerations for the Use of NAMs in Drug Development (Draft Gui…
• Market signal for NAMs vendors and toolmakers. Formal CFR alignment with §355(z) strengthens the business case for organ‑chip platforms, in silico toxicology, and recombinant reagents; FDA’s ISTAND/DDT pathways provide routes to regulatory acceptance that can de‑risk procurement. [7]FDA — New Approach Methodologies (NAMs) | FDA

Social Effects

Distributional consequences span animal welfare, patient safety, and workforce skills.

• Animal welfare baseline and potential reductions. USDA‑reported AWA‑regulated research animal use totaled roughly 774,000 in FY2023; wider adoption of NAMs could reduce demand for regulated species in certain study types, though mice and rats (not AWA‑covered) dominate total usage. [8]USDA APHIS — FY2023 Research Animal Use Summary (PDF)
• Patient safety and access. FDA stresses NAMs must improve predictivity and not dilute safety margins; appropriately validated NAMs could enable safer first‑in‑human dosing and fewer protocol amendments, indirectly supporting faster access. Evidence remains context‑specific. [9]FDA — FDA releases draft guidance on alternatives to animal testing (press rele…
• Workforce transition. Greater reliance on in vitro/in silico methods shifts skill demand toward quantitative toxicology, microphysiological systems, and model validation; NIH’s NAMs RFI responses highlight needs for cell characterization standards and economic assessment to support uptake. [10]NIH Office of Science Policy — NIH NAMs RFI Compiled Report (Nov 2023)

Environmental Effects

Vivaria and high‑containment labs are energy‑ and resource‑intensive; shifting some studies to NAMs may trim those footprints, though quantification depends on local facility mixes.

• Laboratories typically use ~3–8× the energy of offices; design guides cite ~5× as a rule of thumb, with vivaria driven by high ventilation and sanitation demands. Reducing animal housing needs can lower energy, water, and biomedical waste loads at the margin. [11]Lawrence Berkeley National Laboratory — Characterizing the Laboratory Market
• Facility modernization synergies. Institutions pursuing energy upgrades (airflow optimization, heat recovery) can pair NAM adoption with rightsizing of animal space over time, compounding sustainability gains. [12]Whole Building Design Guide (NIBS) — Sustainable Laboratory Design (WBDG)

Temporal Analysis

• Immediate (enactment → year 1). FDA must publish an interim final rule adding §355(z)’s definition to key CFR parts (312/314/315/330/601) and replacing “animal” with “nonclinical,” with immediate effect as authorized by the bill. Sponsors will see updated terminology in submissions and reviewer correspondence. [1]Congress.gov — Text - H.R.2821 - 119th Congress (2025-2026): FDA Modernization…
• Near term (1–2 years). Uptake concentrated in cases with established NAMs (e.g., certain in vitro/in chemico assays, recombinant endotoxin tests), guided by FDA’s general NAMs draft guidance and programmatic support. Training and internal SOP updates dominate costs. [9]FDA — FDA releases draft guidance on alternatives to animal testing (press rele…
• Long term (3–7 years). Greater impact if NAMs demonstrably reduce false negatives/positives in toxicology and are internationally harmonized (e.g., via ICH S1B(R1)‑style updates), enabling convergence across FDA/EMA/others. [13]FDA — S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals (F…

Unintended Consequences

Risks and second‑order effects to monitor.

Assessment

Overall stance: neutral.

On balance, the bill primarily compels textual/regulatory alignment with existing statute and FDA practice. Expected benefits are regulatory clarity and, where scientifically justified, incremental efficiency and welfare/sustainability gains. Realization of broader economic upside depends on disciplined validation, reviewer/sponsor readiness, and international convergence—factors outside the bill’s text but within FDA’s implementation remit. [1]Congress.gov — Text - H.R.2821 - 119th Congress (2025-2026): FDA Modernization…

Key Metrics

Selected reference metrics to contextualize potential impacts.

Sourcing

Principal sources underpinning this analysis (legislative text and actions; FDA policy/guidance; data baselines; technical standards; R&D economics).

• Legislative text and actions: Congress.gov bill text; docs.house.gov bill PDF; House Energy & Commerce releases and markup postings (May 2026). [1]Congress.gov — Text - H.R.2821 - 119th Congress (2025-2026): FDA Modernization…
• Statutory backdrop: Consolidated Appropriations Act, 2023 (FDAMA 2.0); U.S. Code §355 (definition of “nonclinical test”). [2]U.S. Government Publishing Office — Public Law 117-328 (Consolidated Appropriat…
• FDA policy and guidance on NAMs: NAMs program page; draft guidance on general considerations and March 18, 2026 press release; Year‑One progress report. [7]FDA — New Approach Methodologies (NAMs) | FDA
• Animal‑use baseline: USDA APHIS Research Facility Annual Report Summary and FY2023 PDF detail. [15]USDA APHIS — USDA APHIS Research Facility Annual Usage Summary (portal)
• Environmental baselines: WBDG Sustainable Laboratory Design; LBNL laboratory energy intensity; I2SL/Aircuity best practices noting vivarium ventilation drivers. [12]Whole Building Design Guide (NIBS) — Sustainable Laboratory Design (WBDG)
• R&D outcomes and economics: BIO/QLS/Informa clinical success rates; expert elicitation on OoC cost impact; FDA/CDER perspectives on NAMs. [5]BIO / QLS / Informa Pharma Intelligence — Clinical Development Success Rates an…
• Standards and harmonization: ICH S1B(R1) (FDA adoption) and OECD GIVIMP for in vitro method practices. [13]FDA — S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals (F…
• Administrative‑law context for interim‑final rules: APA 5 U.S.C. §553. [16]LII / Cornell Law School — 5 U.S.C. §553 – Rulemaking (APA)